Via direct targeting of TREM2 (triggering receptor expressed on myeloid cells 2), Hecubine alleviated neuroinflammation and oxidative stress in both in vivo (4 dpf zebrafish larvae) and in vitro (BV-2 microglial cells) models, by modulating the Nrf2 and TLR4 signaling pathways (Figure 3C) (Li et al., 2024)
Third, Z
Results showed Cerebrolysin was significantly more effective than placebo for cognitive function at 4 weeks (SMD -0.40, p=0.003), global clinical change at both 4 weeks (OR 3.32, p=0.02) and 6 months (OR 4.98, p=0.015), and combined global benefit (cognitive + clinical) at both timepoints
No side effects except fatigue for the first week or so
Regenerative role of T cells in nerve repair and functional recovery
On April 1, 2026, the FDA approved Foundayo (orforglipron) from Eli Lillythe first oral small-molecule GLP-1 receptor agonist for chronic weight management